Suggested remit: To appraise the clinical and cost effectiveness of finerenone within its marketing authorisation for treating chronic kidney disease in people with type 2 diabetes.
 
Status In progress
Process STA 2018
ID number 3773

Provisional Schedule

Committee meeting: 1 17 February 2022
Expected publication 04 May 2022

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Consultees

Companies sponsors Bayer (finerenone)
Others Department of Health and Social Care
  NHS Eastern Cheshire CCG
  NHS England
  NHS South West Lincolnshire CCG
  Welsh Government
Patient carer groups Kidney Care UK
  UK Kidney Association
Professional groups Association of British Clinical Diabetologists
  Primary Care Diabetes Society
  Royal College of Physicians
  UK Clinical Pharmacy Association

Commentators

Associated public health groups None
Comparator companies AstraZeneca (dapagliflozin)
  Boehringer Ingelheim (empagliflozin)
  Merck Sharp & Dohme (ertugliflozin)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Kidney Patients Association
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
28 June 2021 Invitation to participate
25 June 2021 In progress. In progress
03 March 2021 - 31 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance